Oxidative stress and the pathogenesis of Parkinson's disease

Neurology

Volumn 47, Issue 6 SUPPL. 3, 1996, Pages

  Jenner, Peter ^a   Olanow, C Warren ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; HYDROXYL RADICAL; IRON; MONOAMINE OXIDASE INHIBITOR; NITRIC OXIDE; PEROXYNITRITE; SELEGILINE; SUPEROXIDE DISMUTASE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; BRAIN MITOCHONDRION; DRUG MECHANISM; HUMAN; NERVE CELL LESION; NEUROPROTECTION; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA;

EID: 0029751104     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.47.6_suppl_3.161s     Document Type: Review

References (128)

1. Forno S. Pathology of Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement disorders, neurology 2. London: Butterworth Scientific, 1981:21-40.
2. Golbe LI, Langston JW. The etiology of Parkinson's disease: new directions for research. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Baltimore: Williams and Wilkins, 1993:93-102.
3. Gasser T, Wszolek ZK, Trofatter J, et al. Genetic studies in autosomal dominant parkinsonism: evaluation of seven candidate genes. Ann Neurol 1994;36:387-396.
4. Jenner P, Olanow CW. Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders. In: Olanow CW, Jenner P, Youdim M, eds. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic, 1996:24-45.
5. Jenner P, Marsden CD. MPTP-induced parkinsonism: a model of Parkinson's disease and its relevance to the disease process. In: Marsden CD, Fahn S, eds. Movement disorders, neurology 2. London: Butterworth Scientific, 1981:55-75.
6. Singer TP, Castagnoli N Jr, Ramsay RR, Trevor AJ. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 1987;49:1-8.
7. Adams JD Jr, Odunze IN. Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Biochem Pharmacol 1991;41:1099-1105.
8. Scotcher KP, Irwin I, DeLanney LE, Langston JW, Di Monte D. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion to ATP levels of mouse brain synaptosomes. J Neurochem 1990;54:1295-1301.
9. Youngster SK, Sonsalla PK, Heikkila RE. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 1987;48:929-934.
10. Yoshida M, Niwa T, Nagatsu T. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes. Neurosci Lett 1990;119:109-113.
11. + analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurology 1995;45:2240-2245.
12. McNaught KStP, Thull U, Carrupt P-A, et al. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Pharmacol 1995;50:1903-1911.
13. McNaught KStP, Thull U, Carrupt P-A, et al. Effects of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mitochondrial respiration. Biochem Pharmacol 1996;51:1503-1511.
14. McNaught KStP, Thull U, Carrupt P-A, et al. Inhibition of [3H]dopamine uptake into striatal synaptosomes by isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Pharmacol 1996; 52:29-34.
15. McNaught KStP, Thull U, Carrupt P-A, et al. Toxicity to PC 12 cells of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci Lett 1996;206:37-40.
16. Halliwell B, Gutteridge J. Oxygen radicals and the nervous system. Trends Neurosci 1985;8:22-29.
17. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40:32-37.
18. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson's disease. Proc Natl Acad Sci USA 1989;88:1398-1400.
19. Jenner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease. Neurology 1992;42:2241-2250.
20. Olanow CW, Cohen G, Perl DP, Marsden CD. Role of iron and oxidant stress in the normal and parkinsonian brain. Ann Neurol 1992;32:1-145.
21. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand 1993;87(suppl 146):6-13.
22. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 1994;344:796-798.
23. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
24. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 1991;56:978-982.
25. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 1994;63:793-807.
26. Good P, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study. Brain Res 1992; 593:343-346.
27. Galazka-Friedman J, Bauminger ER, Friedman A, Barcikowska M, Hechel D, Nowik I. Iron in parkinsonian and control substantia nigra: a Mössbauer spectroscopy study. Mov Disord 1996;11:8-16.
28. Sengstock GJ, Olanow CW, Menzies RA, Dunn AJ, Arendash GW. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J Neurosci Res 1993;35:67-82.
29. Ben-Schachar D, Youdim MBH. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem 1991;57:2133-2135.
30. Riederer P, Sofic E, Rausch W-D, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520.
31. Dexter DT, Carayon A, Vidailhet M, et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 1990;55: 16-20.
32. Mann VM, Cooper JM, Daniel SE, Srai K, Marsden CD, Schapira AHV. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994;36:876-881.
33. Connor JR, Snyder BS, Arosio P et al. Quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer diseased brains. J Neurochem 1995;65:717-724.
34. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994;35:38-44.
35. Hirsch EC, Brandel J-P, Galle P, Javoy-Agid F, Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 1991;56:446-451.
36. Temlett JA, Landsberg JP, Watt F, Grime GW. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J Neurochem 1994; 62:134-146.
37. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash G. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 1994;660:8-18.
38. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-1975.
39. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 1992;31:75-83.
40. Valberg LS, Flanagan PR, Kertesz A, Ebers GC. Abnormalities in iron metabolism in multiple sclerosis. Can J Neurol Sci 1989;16:184-186.
41. Leveugle B, Spik G, Perl DP, Constantin B, Fillit HM, Hof PR. The iron-binding protein in lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res 1994;650:20-31.
42. Schapira AHV. Evidence for mitochondrial dysfunction in Parkinson's disease: a critical appraisal. Mov Disord 1994;9: 125-138.
43. Lestienne P, Nelson J, Riederer P, Jellinger K, Reichmann H. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J Neurochem 1990; 55:1810-1812.
44. Ikebe S-I, Tanaka M, Ozawa T. Point mutations of mitochondrial genome in Parkinson's disease. Mol Brain Res 1995;28: 281-295.
45. +) in the pathogenesis of Parkinson's disease. Brain Res 1992;575: 285-298.
46. Mytilineou C, Werner P, Molinari S, et al. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease. J Neural Transm 1994;8:223-228.
47. Mizuno Y, Matuda S, Yoshino H, Mori H, Hattori N, Ikebe S-I. An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 1994; 35:204-210.
48. Mastrogiacomo F, Bergeron C, Kish SJ. Brain α-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. J Neurochem 1993;61:2007-2014.
49. Gaitonde MK, Murray E. The effect of conditions of homogenization on the activity of pyruvate dehydrogenase and its stability in brain homogenates. Neurochem Int 1989;15:355-358.
50. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992;31:119-130.
51. Marttila RJ, Lorentz H, Rinne UK. Oxygen toxicity protecting enzymes in Parkinson's disease: increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 1988;86:321-331.
52. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 1994;36:356-361.
53. Kish SJ, Morito C, Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 1985;58: 343-346.
54. Ambani LM, Van Woert MH, Murphy S. Brain peroxidase and catalase in Parkinson disease. Arch Neurol 1975;32: 114-118.
55. Dexter DT, Ward RJ, Wells FR, et al. α-Tocopherol levels in brain are not altered in Parkinson's disease. Ann Neurol 1992;32:591-593.
56. Saggu H, Cooksey J, Dexter DT, et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989;53:692-697.
57. Marklund S, Adolfsson R, Gottfries C, Winblad B. Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of Alzheimer type. J Neurol Sci 1985;67:319-325.
58. Yoshida E, Mokuno K, Aoki S-I, et al. Cerebrospinal fluid levels of superoxide dismutases in neurological diseases detected by sensitive enzyme immunoassays. J Neurol Sci 1994;124:25-31.
59. Przedborski S, Kostivc V, Jackson-Lewis V, et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistent to MPTP-induced neurotoxicity. J Neurosci 1992; 12:1658-1667.
60. Nakao N, Frodl EM, Widner H, et al. Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nature Med 1995; 1:224-231.
61. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency. Neurosci Lett 1982; 33:305-310.
62. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355.
63. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992;142:128-130.
64. Pearce RKB, Owen A, Daniel S, Jenner P, Marsden CD. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. Neuroscience 1996.
65. DeLeve LD, Kaplowitz N. Glutathione metabolism and its role in hepatotoxicity. Pharmacol Ther 1991;52:287-305.
66. Mithöfer K, Sandy MS, Smith MT, Di Monte D. Mitochondrial poisons cause depletion of reduced glutathione in isolated hepatocytes. Arch Biochem Biophys 1992;295:132-136.
67. Spencer JPE, Jenner P, Halliwell B. Superoxide-dependent depletion of reduced glutathione by L-dopa and dopamine: relevance to Parkinson's disease. Neuroreport 1995;6:1480-1484.
68. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
69. Olanow CW, Arendash G. Metals and free radicals in neurodegeneration. Curr Opin Neurol 1994;7:548-558.
70. Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994;9:92-97.
71. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc Nat Acad Sci USA 1996;93:2696-2713.
72. Sanchez-Ramos J, Overvik E, Ames BN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994;3:197-204.
73. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: a selective increase in 8-hydroxyguanine in substantia nigra? J Neurochem 1996.
74. Spencer-Smith T, Parker WD Jr, Bennett JP. L-Dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity? Neuroreport 1994;5:1009-1011.
75. Spencer JPE, Jenner A, Aruoma OI, et al. Intense oxidative DNA damage promoted by L-dopa and its metabolites: implications for neurodegenerative disease. FEBS Lett 1994;353: 246-250.
76. Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC 12 cells by L-dopa: implications for the treatment of Parkinson's disease. J Clin Invest 1995;95: 2458-64.
77. Hefti F, Melamed E, Bhawan J, Wurtman R. Long term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195.
78. Perry TL, Young VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984;43: 990-993.
79. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-133.
80. Ogawa N, Asanuma M, Kondo Y, et al. Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci Lett 1994;171:55-58.
81. Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal: applications in research and therapy. Pharmacol Ther 1991;51:155-194.
82. Kokotos, Leonardi ET, Cheng B, et al. L-Dopa and L-deprenyl protect against L-BSO induced cell death in cultured mesencephalic neurons. Soc Neurosci Abstr 1996 (in press).
83. Toffa S, Kunikowska GM, Zeng B-Y, Jenner P, Marsden CD. Chronic glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J Neural Transm Park Dis Dement Sect 1996.
84. Pileblad E, Magnusson T, Fornstedt B. Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum. J Neurochem 1989;52:978-980.
85. + toxicity in nigral dopaminergic neurones. Neuroreport 1996;7:921-923.
86. Seaton TA, Jenner P, Marsden CD. Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain. J Neural Transm 1996;103:315-329.
87. Heales SJR, Davies SEC, Bates TE, Clark JB. Depletion of brain glutathione is accompanied by impaired mitochondrial function and decreased N-acetyl aspartate concentration. Neurochem Res 1995;20:31-38.
88. Jain A, Martensson J, Stole E, Auld PAM, Meister A. Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci USA 1991;88:1913-1917.
89. +. J Neural Transm Gen Sect 1992;89:139-145.
90. +. Free Radic Biol Med 1992;13:581-583.
91. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993;16:439-444.
92. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-1624.
93. Mufson EJ, Brandabur MM. Sparing of NADPH-diaphorase striatal neurons in Parkinson's and Alzheimer's diseases. Neuroreport 1994;5:705-708.
94. Hunot S, Boissière F, Faucheux B, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996;72:355-363.
95. Kaur H, Halliwell B. Evidence for nitric oxide-mediated damage in chronic inflammation: nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett 1994;350: 9-12.
96. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence for neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996;149:21-28.
97. Ischiropoulos H, Zhu L, Chen J, et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 1992;298:431-437.
98. Reif DW, Simmons RD. Nitric oxide mediates iron release from ferritin. Arch Biochem Biophys 1990;283:537-541.
99. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 1991; 288:481-487.
100. Cleeter MWJ, Cooper JM, Darley-Usmar VM, Moncada S, Schapira AHV. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide: implications for neurodegenerative diseases. FEBS Lett 1994;345:50-54.
101. Bolanos JP, Peuchen S, Heales SJR, Land JM, Clark JB. Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. J Neurochem 1994;63: 910-916.
102. Cleeter MWJ, Cooper JM, Schapira AHV. Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J Neurochem 1992;58:786-789.
103. +-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. Neuroreport 1994;5:2598-2600.
104. +-evoked hydroxyl radical formation but not dopamine efflux in rat striatum. J Neural Transm GenSect 1996 (submitted).
105. Schulz JB, Matthews RT, Muqit MMK, Browne SE, Beal MF. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995;64:936-939.
106. Przedborski S, Jackson Lewis V, Yokoyama R, Shibata T, Dawson VL, Dawson TM. Role of neuronal oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 1996;93: 4565-4654.
107. +-induced cell injury in the striatum of rats. Br J Pharmacol 1994;111:837-842.
108. Beal MF. Therapeutic effects of nitric oxide synthase inhibition in neuronal injury. In: Olanow CW, Jenner P, Youdim M, eds. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press, 1996;91-101.
109. MacKenzie GM, Jackson MJ, Jenner P, Marsden CD. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset. Synapse 1996.
110. Kelly PAT, Ritchie IM, Arbuthnott GW. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole: effects upon local cerebral blood flow and glucose use in the rat. J Cerebral Blood Flow Metab 1995;12:311-317.
111. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. New Eng J Med 1989;321:1364-1371.
112. + in vivo. Eur J Pharmacol 1993;243:241-247.
113. Tatton WG, Ju WYL, Holland DP, et al. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994;63:1572-1575.
114. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW. L-Deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity. J Neurochem 1996 (in press).
115. +. J Neural Transm 1989;76:1-12.
116. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984;311:467-469.
117. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 1985;106:209-210.
118. Kindt MV, Youngster SK, Sonsalla PK, Duvoisin RC, Heikkila RE. Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2′Me-MPTP. Eur J Pharmacol 1988;146: 313-318.
119. Naoi M, Matsuura S, Parvez H, et al. Oxidation of N-methyl-1,2,3,4-tetrahydroisoquinoline into the N-methyl-isoquinolinium ion by monoamine oxidase. J Neurochem 1989;52: 653-655.
120. Minami M, Maruyama W, Dostert P, Nagatsu T, Naoi M. Inhibition of type A and B monoamine oxidase by 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines and their N-methylated derivatives. J Neural Transm Gen Sect 1993; 92:125-135.
121. Mytilineou C, Cohen G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenyl-pyridinium ion. J Neurochem 1985;45:1951-1953.
122. Tatton WG, Ju WYH, Wadia J, Tatton NA. Reduction of neuronal apoptosis by small molecules: promises for new approaches to neurological therapy. In: CW Olanow, P Jenner, MHB Youdim, eds. Neurodegeneration: and neuroprotection. London: Academic, 1996:209-220.
123. Clow A, Hussain T, Glover V, Sandler M, Dexter DT, Walker M. (-)Deprenyl can induce soluble superoxide dismutase in rat striata. J Neural Transm Gen Sect 1991;86:77-80.
124. Carrillo M-C, Kanai S, Nokubo M, Ivy GO, Sata Y, Kitani K. (-)Deprenyl increases activities of superoxide dismutase and catalase in striatum but not in hippocampus: the sex and age-related differences in the optimal dose in the rat. Exp Neurol 1992;116:286-294.
125. Carrillo MC, Kanai S, Sato Y, Ivy GO, Kitani K. Sequential changes in activities of superoxide dismutase and catalase in brain regions and liver during (-)deprenyl infusion in male rats. Biochem Pharmacol 1992;44:2185-2189.
126. Lai CT, Zuo DM, Yu PH. Is brain superoxide dismutase activity increased following chronic treatment with L-deprenyl? J Neural Transm 1994;41(suppl):221-229.
127. Tatton WG, Chalmers-Redman RME. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 1996;47(suppl 3):S171-S183.
128. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of signs and symptoms in Parkinson's disease. Ann Neurol 1995;38:771-777.